FLT3 and acute myeloid leukemia: Gilteritinib, an agent with activity against wild‐type FLT3, FLT3/ITD, FLT‐TKD D835 and F691, as well as Axl, has been examined for the treatment of relapsed/refractory AML in two early‐phase clinical trials.